Introduction {#s1}
============

Idiopathic pulmonary fibrosis (IPF) is a progressive disease characterised by increased scarring of lung tissue \[[@C1]\]. Despite the recent introduction of novel drugs that slow disease progression (namely pirfenidone and nintedanib), IPF remains a deadly disease, and the benefits of these new drugs differ markedly between patients \[[@C2]\]. Furthermore, additional anti-fibrotic compounds have failed to demonstrate efficacy in IPF, probably because of limitations in the translation of pre-clinical studies into humans ([figure 1](#F1){ref-type="fig"}) \[[@C3]\]. To improve the prognosis of individual IPF patients it is essential to move the field toward a personalised medicine approach \[[@C4]\]. In this context, we need to better understand the multilevel, network-based biological complexity of IPF ([figure 2](#F2){ref-type="fig"}). Systems biology is a novel research strategy that seeks, precisely, to understand the so-called "emergent properties" of complex biological systems (such as clinical presentation or treatment response) and to understand disease heterogeneity by identifying links and assessing individual risk of developing a disease at different network levels (molecular, cellular, clinical and environmental) \[[@C5]\]. Thus, systems biology is ideally suited to move the field of IPF towards a most needed precision medicine scenario.

![Systems biology as a tool to improve idiopathic pulmonary fibrosis (IPF) treatment effectiveness. Harnessing the power of systems biology may provide explanations for discrepancies between *in vitro*/*in vivo* experiments and clinical trial results. These indicators can then be incorporated into more finely tuned experiments, which should result in more effective treatments.](00106-2017.01){#F1}

![Translation from endotype to phenotype, variants and comorbidities. Four main biological networks are involved in idiopathic pulmonary fibrosis (IPF) that include several key elements of the accelerated ageing and lead to the consequent altered wound healing. 1) Cellular network: mesenchymal stem cells (MSCs), alveolar epithelial cells (AECs), extracellular matrix (ECM), fibroblasts, myofibroblasts, macrophages, senescence, mitochondrial dysfunction, apoptosis, autophagy. 2) Metabolic regulation network: hormones, soluble mediators, cell metabolism. 3) Genetic network: *MUC5B*, SFTPC/SFTPA, telomerase complex, epigenetics. 4) Environmental network: smoking, pollution, gastro-oesophageal reflux (GOR), dust, microbiome. The interconnection among the different players and the clinical repercussions of this complex integrative model is not completely understood. Systems biology is probably the perfect tool to finally shed light on these elusive questions. PAH: pulmonary arterial hypertension.](00106-2017.02){#F2}

To address these issues, the Scientific Committee of the European Respiratory Society (ERS), in collaboration with the ERS group on diffuse parenchymal lung disease, organised a Research Seminar in Barcelona, Spain on December 15--16, 2016 (<http://www.ers-education.org/events/research-seminars/integrating-systems-biology-approach-in-idiopathic-pulmonary-fibrosis-research,-barcelona-2016.aspx>). The major conclusion of this seminar was the need to design, organise, launch and support a global initiative for fibrosis treatment (GIFT), based on international translational research collaboration and a comprehensive, systems-biology based approach to the disease. An organisation like GIFT would have the potential to move the field of IPF forward quickly and effectively to improve understanding and to identify an effective treatment. This report summarises the topics discussed durign this research seminar that lead to the proposal for GIFT.

Current research in IPF: the need to integrate multi-level network complexity {#s2}
=============================================================================

[Figure 2](#F2){ref-type="fig"} presents a graphical representation of four networks (genetic, cellular, metabolic and environmental) with potential impacts not only on disease development, progression and response to therapy, but also to the different variants or phenotypes of the disease. Dissecting and integrating them is essential to establish a better understanding of the disease and for development of novel therapies.

Genetic network {#s2a}
---------------

IPF is a complex genetic disorder \[[@C6]--[@C8]\]. At least eight different genes (*MUC5B*, *TERT*, *TERC*, *RTEL1*, *PARN*, *SFTPC, SFTPA1* and *SFTPA2*) and 11 gene variants in novel loci have been associated with the disease \[[@C9]\]. A common gain-of-function promoter variant in the MUC5B gene (rs35705950) accounts for 30--35% of the risk for developing IPF and can potentially help identify subjects with a higher risk or patients with preclinical pulmonary fibrosis \[[@C9]\]. Mechanistically, this MUC5B variant appears to decrease mucociliary clearance, which can then enhance cell injury and alter wound repair \[[@C9]\].

Another important hub in the genetic IPF network relates to mechanisms of cell ageing. The discovery of telomerase and telomere functions received the Nobel Prize in Medicine in 2009 \[[@C10]\], and the role of telomerase and telomere attrition in ageing and other diseases has been well established \[[@C11], [@C12]\]*.* Telomere length decreases with cell division (*i.e.* with physiological ageing). If telomeres are shortened, cells age. Conversely, if telomerase activity is high, telomere length is better maintained and cellular senescence is delayed. For instance, this is the case for cancer cells, which can be considered immortal. In IPF, telomerase gene mutations and reduced telomere length are highly prevalent \[[@C13], [@C14]\]. Telomerase dysfunction and telomere shortening are associated with increased cell senescence and cell damage \[[@C15]\]. Interestingly, telomerase gene mutations have been associated with poor prognosis in IPF \[[@C13], [@C14]\], and the severity of telomere attrition correlates with disease progression and outcome \[[@C16]\]. Further, age-related cell perturbations found in epithelial cells and fibroblasts of patients with IPF are not present in normal lungs of similar age individuals \[[@C17]\]. However, while it is well established that familial forms of IPF are linked to dysfunctional telomerase activity and mutations in surfactant proteins, the relationship of ageing to the majority of sporadic IPF cases is currently under study. Finally, in addition to telomere attrition, there are other genetic footprints associated with accelerated ageing, including genomic instability and epigenetic changes \[[@C18]\], which can also be relevant to the pathobiology of IPF. Interventions to modify these age-related characteristics are currently being investigated in IPF \[[@C19]\], since the lung-ageing process appears to be associated with the generation of a vulnerable alveolar epithelium, as well as a reduction of enzymes involved in telomere maintenance \[[@C20]\].

Cellular network {#s2b}
----------------

Traditionally, the two cellular actors considered most relevant in IPF were alveolar epithelial cells (AECs) and myofibroblasts, respectively. Recent research applying single cell sequencing approaches provides evidence for the existence of several subpopulations of AECs and a variety of interstitial fibroblasts and other mesenchymal cells. Furthermore, mesenchymal stem cells (MSCs) have also been shown to be important cellular actors involved in the pathogenesis of lung fibrosis.

AECs are essential for normal lung function, forming the tight functional barrier required for gas exchange \[[@C21]\]. Under normal conditions, alveolar type II (ATII) cells act as progenitor cells that initiate alveolar epithelial repair and restoration, giving rise to either new ATII cells or differentiation into alveolar type I cells \[[@C22]\]. However, activated AEC\'s can participate in the fibrogenic response by secreting mesenchymal proteins \[[@C23]\]. In IPF, reprogramming of these cells results in a number of different phenotypes and functions, which include proliferation and bronchiolisation, apoptosis, and acquisition of mesenchymal features \[[@C24], [@C25]\].

Fibroblasts and myofibroblasts are considered the key effector cells in the fibrogenic response in IPF and a hub within the cellular network because they are responsible for the large amount of ECM production in the fibrotic tissue \[[@C26]\]. Yet, there are still many unanswered questions in relation to fibroblasts. For instance, we do not know if there is only one specific phenotype of fibrotic fibroblast or a variety \[[@C27]\], what the origin may be of the accumulating myofibroblasts in the IPF lung, and the identity of the main pathways driving proliferation and differentiation of these heterogeneous cells \[[@C28]\]. From a network perspective, given that fibroblasts in the alveolus live in close contact with AECs, it is crucial to understand what mechanisms link epithelial injury and fibroproliferation.

With particular importance for the systems biology and cross-network perspective, alveolar macrophages seem to be particularly affected by the pro-fibrotic environment of IPF lungs, which deregulates functionality in wound-healing and repair \[[@C29]\], leading to studies on the downstream implications of high levels of oxidised mitochondria.

Finally, another key consideration relates to the role of MSCs in IPF \[[@C30]\]. As discussed earlier, mechanisms associated with ageing participate in the pathobiology of IPF. Part of this ageing process includes the exhaustion of MSCs and the changes in the function of bone marrow (BM)-MSCs that depend on age \[[@C17], [@C31]\]. Interestingly, harvested aged MSCs are less effective in preventing fibrotic changes than MSCs from young animals \[[@C32]\]. In addition, MSCs from IPF patients have smaller mitochondria and undergo accelerated senescence \[[@C18], [@C31]\]. The functional and clinical implications of these observations merit further investigation \[[@C18]\].

Metabolic regulation network {#s2c}
----------------------------

Metabolism is a key player in biological complexity \[[@C33]\]. For example, in cancer it is well established that rapid cell proliferation is associated with increased glucose uptake (which can be detected by increased uptake of 18F-FDG (2-fluoro-2deoxy-[d]{.smallcaps}-glucose) on positron emission tomography (PET)) \[[@C34]\]. IPF lungs also present increased uptake of 18F-FDG \[[@C35], [@C36]\], and recent studies have shown that metabolic reprogramming plays a key role in fibroproliferation and myofibroblast differentiation \[[@C37], [@C38]\]. Classically, several growth factors, cytokines and hormones have been reported to act in cell-to-cell and cell-to-extracellular matrix (ECM) cross-interactions, inducing different cell metabolic and fibrotic changes. Furthermore, mechanical ECM properties, such as increased stiffness, also contribute to influencing cell phenotype. More recently, a number of hallmarks of ageing such as accumulation of misfolded proteins and dysfunctional mitochondria, dysregulation of miRNA expression, and deficient autophagy have been described to contribute to increasing the pro-fibrotic response and modifying cell behaviour and metabolism \[[@C12], [@C18]\].

Environmental network {#s2d}
---------------------

Cells and tissues (hence gene, proteins and metabolites) are constantly exposed to dynamic micro- and macro-environmental changes (*e.g.* smoking, the microbiome, pollution and/or gastro-oesophageal reflux (GOR)) that can modulate their interaction, changing the endotype and, consequently, the phenotype \[[@C39]--[@C41]\]. Smoking exposure increases the probability of the associated emphysema. The treatment of GOR is recommended in the updated IPF guidelines since, when present, it may increase AEC cell injury \[[@C2], [@C39]\]. The most recent advances in the knowledge of microbiome postulate that the bacterial signature induces a host response, which may play a role in disease behaviour and therefore represent another target to prevent or treat \[[@C41]\].

Systems biology: well suited for the complexity of IPF research {#s3}
===============================================================

Systems biology is an iterative research strategy ([figure 2](#F2){ref-type="fig"}). The process generally starts with collection of multi-dimensional data (genomics, transcriptomics, metabolomics, microbiomics, *etc.*). The input variables are rather infinite, but using computational biology, models that aggregate emergent properties can be created and then challenged by experimental intervention. In this context, network analysis is a powerful technique to better visualise complex biological systems using graphs. This process is iterated until the resulting model reflects with sufficient accuracy the experimental findings \[[@C42]\]. S[elman]{.smallcaps} and P[ardo]{.smallcaps} \[[@C43]\] have already used this approach to propose an integral model of IPF in which a combination of gene variants results in a loss of epithelial integrity that, in turn, limits the capacity of alveoli to respond to injury. Thereafter, epigenetic reprogramming takes place and affects epithelial cells and fibroblasts, resulting in destruction of the lung tissue \[[@C43]\].

Following discussions on current research in IPF, participants in the ERS seminar agreed that a systems biology approach has great potential to understand better IPF pathobiology, differences in clinical phenotypes and response to therapy as well as correlations with the clinical expression of IPF variants ([figure 3](#F3){ref-type="fig"}). Yet, in order to achieve these goals the following critical requirements should be considered and implemented.

![Iterative working phases of systems biomedicine. Systems biology is a process that becomes highly honed as new information is aggregated, filtered, tested, and allocated as essential data for further cycling through the four steps. Several lines of investigation may result. Reproduced from \[[@C44]\] with permission. ©Permanyer 2017.](00106-2017.03){#F3}

Standard operating procedures {#s3a}
-----------------------------

Interoperability of diverse data is critical. Current ongoing studies, such as PROFILE \[[@C45]\] and the European IPF network registry \[[@C46]\] collect different biological samples to work collaboratively on IPF diagnosis and monitoring, and are already using a shared set of predefined rigorous standard operating procedures (SOPs).

Cooperative biobank {#s3b}
-------------------

Accessing a large number of biological samples sampled and stored according to SOPs, particularly those obtained in the early phases of the disease, has the potential to identify novel key pathobiological mechanisms and biomarkers that facilitate the discovery of new treatments to prevent disease progression. By combining efforts in sample collection at different academic centres, a larger and more comprehensive biobank could be made available to all IPF researchers, after appropriate assessment of the scientific value and priority of the project proposed \[[@C47]\]. The Global IPF Collaborative Network ([www.ucdenver.edu/academics/colleges/medicalschool/departments/medicine/globalipf/Pages/GlobalIPF.aspx](www.ucdenver.edu/academics/colleges/medicalschool/departments/medicine/globalipf/Pages/GlobalIPF.aspx)) with a DNA consortium is a successful example of this type of initiative \[[@C48]\], with various types of IPF samples (*e.g.* surgical lung biopsies, cryobiopsies and cryopreserved cells).

Education and support on novel bioinformatics techniques {#s3c}
--------------------------------------------------------

Systems biology approaches rely heavily on novel bioinformatics analyses. Most basic and clinical research centres do not yet have the necessary educational framework and bioinformatics expertise in place to take advantage of rapidly evolving bioinformatics approaches, which is also crucial for interpretation of results.

The global initiative for fibrosis treatment (GIFT) {#s4}
===================================================

Participants in the seminar unanimously agreed that an organisation specifically tailored to foster top-notch, cooperative, international IPF research was needed to promote the discovery, development and implementation of more effective and precise (*i.e.* personalised) treatment options for IPF. To achieve this, it was proposed to connect existing IPF networks across the globe and build upon databases from previous initiatives such as the ERS pan-European IPF registry and biobank (ARIANE-IPF) and the eurIPFreg and eurIPFbank ([www.pulmonary-fibrosis.net](www.pulmonary-fibrosis.net)) \[[@C46]\]. In addition, national patient groups could be aligned to move patient treatment forward with equal access and standards as proposed in the European IPF Patient Charter ([www.ipfcharter.org](www.ipfcharter.org)). Pharmaceutical and biotechnology partners could also be welcomed. The participants suggested this new body could undertake the directive of setting the standards and regulation needed for an integrated research network across the IPF community that leverages the potential of systems biology \[[@C49]\]. This body could potentially be named the "Global initiative for fibrosis treatment" (GIFT), which could also apply for and allocate specific research funds, establish connections between biobanks to support cutting-edge research, and develop global strategies for IPF challenges.

Participants in the seminar concluded that the next ERS International Congress in Milan (Italy) in September 2017 would be an ideal forum to develop these ideas further, establish specific goals, and determine task allocation (organisation, chairmanship, frequency of meetings) and short-term milestones. The first priority for the proposed body is an inclusive invitation to contribute to this worldwide initiative and to design a governance document, to establish directives, functions, and responsibilities, which was presented at the ERS International Congress in Milan. Secondly, it must be determined by quorum, including all the relevant international experts, how these goals will be achieved. Due to the costly nature of biomedical research, finding funds for the logistic implementation of GIFT is also required. The GIFT initiative was approved by the ILD assembly of the ERS during the ERS International Congress in Milan.

All in all, GIFT would then have the potential to direct and facilitate the highest-quality integrative research with the final goal of finding novel, effective, and safe therapies for this complex and lethal disease.
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